Brittany Stanley is a Staff Counsel at Dava CRO. Brittany is part of the Global Clinical Development and Operations team where she negotiates clinical trial agreements, manages regulatory processes, and ensures compliance with the many laws and regulations governing Clinical Trials. Brittany and the team are currently in the process of opening two Global Phase III Clinical Trials.
Brittany was born and raised in Billings, Montana and attended Montana State University – Billings where she earned a Bachelor of Science Degree in Criminal Justice and Bachelor of Science in Sociology. Brittany earned her Juris Doctor from California Western School of Law in San Diego where she took an interest in the Pharmaceutical Industry and began interning in the field. Brittany is now a licensed attorney in both Texas and California.
Francesca joined DAVA CRO as an Operational Coordinator in November 2018. She has a legal back ground and she is legally qualified to practice law in Italy. She is a PhD candidate in comparative law at the European University of Rome. When she was living in Italy she worked for a law firm specialized in civil and commercial law. Her experience in Italy also includes working in a law firm in the department of antitrust and corporate services. She worked also for the Italian Competition Authority, which is an independent agency, as a trainee for the department of Competition in Communication Services. This position was obtained through a public contest based on merit. Her native language is Italian and she speaks Portuguese fluently because lived 2 years in Brazil and English with high proficiency.
Dr. Bridget Hindman join DAVA CRO in August 2018, where she works on a variety of projects relating to acute myeloid leukemia. She received a Bachelor of Science in Molecular Biology and Criminology from the University of Texas at Dallas, and then attended West Virginia University, where she earned a PhD in Cancer Cell Biology. Her dissertation work focused on the role of motor proteins in cancer cell interactions with the surrounding collagen matrix and the resulting changes in the mechanobiology of the matrix. Through her participation in NIH funded training grants, Dr. Hindman gained knowledge and experience in a wide variety of biomedical research topics and worked with a team of graduate students across several institutions to host a regional conference funded by the American Society for Cell Biology.
Dr. Hindman then transitioned into a postdoctoral position at the National Institute for Occupational Safety and Health where she received training in toxicology and worked on research projects related to the role of occupational exposure to nanoparticles in the development of pulmonary fibrosis. During her PhD and postdoctoral training Dr. Hindman authored several research articles, a book chapter, and presented in many conference presentations.
Alex joined DAVA CRO in March 2017, where he initially served in a variety of data analysis roles before turning his focus to managing the patient enrollment and pharmacovigilance processes for Arog Pharmaceuticals’ ongoing Phase III AML trials. Prior to joining the CRO, he spent several years working in academic research, including time as a lab manager in the Molecular Biology department at UT Southwestern Medical Center.
Alex received his undergraduate degree in Biochemistry and Cell Biology and Ecology and Evolutionary Biology from Rice University in 2013, followed by a Master of Public Health in Healthcare Management from the University of Texas in 2016.
Jessica Lee is an eTMF research coordinator in DAVA CRO. She manages electronic Trial Master File for AML phase II trials and the solid tumor Phase III trial. She works in clinical research field since 2017.
She received her Master of Science in Molecular Cell Biology from the University of Texas at Dallas on 2016. Before joining the clinical trial industry, Jessica became interested in research and worked at Dodani lab at biochemistry department in UT Dallas, using directed evolution to produce florescence chloride protein sensor base on the microbial rhodopsin. Jessica received a Bachelor of Science in Life Science, major in Biodiversity and Ecology from Tunghai University, Taiwan.
Dr. Hyuntae Yoo joined Dava CRO in September 2018 and is currently the project manager of the solid tumor projects and various statistical projects. Dr. Yoo’s extensive knowledge and experience on these areas originate primarily from his independent research on lung cancer biomarker discovery and preclinical/clinical validation at the University of Texas at Dallas (UTD) as a junior faculty member and a principal investigator. Dr. Yoo also built his communication skills through teaching biochemistry for undergraduate and graduate students at UTD. Prior to this position, Dr. Yoo received postdoctoral training in systems biology (in such projects as prion disease and drug-induced liver toxicity) at the Institute for Systems Biology under Dr. Leroy Hood. His doctoral training at the Massachusetts Institute of Technology was in Biochemistry with emphasis on metabolic analysis of fat synthesis. He received Summa Cum Laude during his undergraduate education in Chemistry (esp. in synthetic organic chemistry) at Seoul National University.